ClinicalTrials.gg
RecruitingNCT05873881COLT-HFUpdated Oct 2, 2026

COLchicine and Thiamine in Heart Failure Due to Ischemic Heart Disease

A Phase 3 interventional study of Colchicine 0.5 MG and Colchicine placebo in Heart Failure, sponsored by Hamilton Health Sciences Corporation. Recruiting at 1 site in Canada. Open to participants aged 45 Years and older. Per ClinicalTrials.gov, last updated 2026-10-02.

Sponsored by Hamilton Health Sciences Corporation · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jan 2024; still recruiting 2 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
2,500
Allocation
Randomized
Ages
45 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 454 studies in Heart Failure with a site in Canada — 77 open to participants now, 99 under way, 21 of them phase 3. Heart Failure · Canada.

Planned enrollment
45th of 362
2,500 · median 226
Started
2024
with 26 others
Phase 3
94 of 454
16 open now
Primary completion
2027-06
later than 51 of 98 live
Registered
395th of 454
by date

Among the 454 studies in Heart Failure with a site in Canada, this one is the 45th largest by planned enrollment of the 362 interventional ones that give a count, is one of 27 that started in 2024, is one of 94 in phase 3, reaches primary completion later than 51 of the 98 other live ones, and was the 395th registered.

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

77 of the 454 studies in Heart Failure with a site in Canada are open now. Recruiting first, the newest first:

72 more — sign in →

All 77 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 45 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 454 studies in Heart Failure with a site in Canada, or all of them as a file.
02

Study summary

The goal of this 2x2 factorial clinical trial is to test the efficacy of i) colchicine, and ii) thiamine in heart failure (HF) secondary to ischemic heart disease. The main questions it aims to answer are:

  • Does colchicine reduce the risk of cardiovascular (CV) death, a HF event, or an ischemic CV event
  • Does thiamine reduce the risk of cardiovascular (CV) death, or a HF event

Participants will undergo the following procedures:

  • Run-in: All participants will receive colchicine 0.5 mg daily to assess drug tolerance over a 3-4 week period.
  • Randomization: If colchicine is tolerated during run-in, eligible participants will be randomized in a 2x2 factorial design to receive i) colchicine 0.5mg daily or placebo, and ii) thiamine 300mg daily or no thiamine.
  • Follow-up: Clinical outcomes, side effects, adverse events, and drug adherence will be captured during follow-up
03

Conditions studied

  • Heart Failure

Browse trials for

04

Who can participate

Ages eligible
45 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age >/= 45 years
  2. Documented ischemic HF as the etiology of HF, which includes:

    1. a prior history of CAD (defined as a history of myocardial infarction, coronary artery bypass graft surgery, percutaneous coronary intervention, or non-invasive or invasive cardiac testing consistent with a diagnosis of CAD), and
    2. determination of CAD to be the cause primary cause of HF based on local investigator assessment
  3. (NYHA) class II-IV symptoms
  4. Documented \</= 45% within 1 year prior to enrollment
  5. Optimization of HF treatment based on local practice.
  6. Ambulatory HF patients or stable hospitalized patients with HF will both be eligible for enrollment in the trial. For hospitalized patients, enrollment will require i) evidence of clinical stability from HF defined as no use of an inotropic agent or intravenous diuretic agent in the prior 24, and ii) expected discharge from hospital in the next 72 hours.

Exclusion criteria

Exclusion Criteria:

  1. Female who is pregnant, breast-feeding, or of and not using an effective form of *
  2. Regular or required use colchicine or thiamine for other clinical indications.**
  3. History of allergic reaction to colchicine or to thiamine; or current or planned use of cyclosporine, verapamil, diltiazem, azole antifungal, macrolide antibiotic (except azithromycin), or protease inhibitor
  4. Use of a ventricular assist device or prior heart transplant
  5. Coronary revascularization (coronary artery bypass graft surgery or percutaneous coronary intervention) within the 4 weeks prior to enrollment, or planned within the next 4 weeks.
  6. Severe valvular disease
  7. Chronic and severe renal dysfunction defined as \< 15 mL/min/1.73m2 based on local laboratory measurement done within 6 months prior to run-in***
  8. History of liver cirrhosis
  9. Active (excluding basal cell or treated squamous cell carcinoma of the skin) requiring treatment and with a life-expectancy of \< 2 years.
  10. Concurrent use of other experimental pharmacologic agents -
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Factorial assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
2,500 participants (estimated)

Study arms

  • Placebo comparator
    Colchicine versus placebo

    Randomization to colchicine or placebo

    Drug: Colchicine 0.5 MG · Drug: Colchicine placebo

  • Experimental
    Thiamine versus no thiamine

    Randomization to thiamine or to no thiamine in a PROBE design

    Drug: Thiamine Mononitrate 300 mg

Interventions

  • DrugColchicine 0.5 MG

    Oral colchicine 0.5 mg daily

  • DrugColchicine placebo

    Placebo colchicine daily

  • DrugThiamineStudies of ThiamineThiamine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Thiamine Mononitrate 300 mg daily

06

What researchers measure

Primary outcomes

  1. Colchicine arm: Time to first occurrence of a CV death, a HF event, MI, stroke, or arterial revascularization

    Time frame: 3.5 years

  2. Thiamine arm: Time to first occurrence of a CV death, or a HF event

    Time frame: 3.5 years

Secondary outcomes

  1. Time to death

    Time frame: 3.5 years

  2. Time to first hospitalization

    Time frame: 3.5 years

07

Study locations

1 of 1 sites recruiting
  • Hamilton Health Sciences Corporation
    Hamilton, Ontario L8L 2X2, Canada
    Recruiting
    • Katie Porter · Contactporterk@hhsc.ca · 905-521-2100
    • Phil G. Joseph, MD · Principal investigator
    • Eva Lonn, MD · Sub investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2024 (actual). Primary completion is estimated for Jun 2027, 41 months after the start.

Of 87 non-industry phase 3 interventional studies under Heart Failure, half reached primary completion within 50 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 63. This study's planned 41 months is below that.

Counting every sponsor, half of 150 studies reached it within 39 months; a quarter within 26 and three quarters within 57.

How these figures are worked out, and which studies are left out of them.

Registered
May 15, 2023
First posted
May 24, 2023
StartActual
Jan 29, 2024
Primary completionEst.
Jun 2027
CompletionEst.
Jun 2027
Last update
Oct 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date, oversight details and index terms
1 update, last Oct 2, 2026
Show all 1 update
  1. Oct 2, 2026
    Minor edits only
    + 3 other changes: verification date, oversight details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05873881
Collaborators
Population Health Research Institute, Canadian Institutes of Health Research (CIHR)
Responsible party
Sponsor
First posted
May 24, 2023
Start date
Jan 29, 2024
Primary completion
Jun 2027 (estimated)
Completion
Jun 2027 (estimated)
Last update
Oct 2, 2026

Study contacts

Philip G Joseph, M.D.
Contact
philip.joseph@phri.ca
905-521-2100 ext. 40743
Philip G Joseph, M.D.
principal investigator · Population Health Research Institute

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Thiamine

Start the discussion